ML
Therapeutic Areas
ArcticZymes Technologies ASA Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ArcticZymes Enzyme Portfolio (e.g., UDG, DNase I) | Research Use / Molecular Biology Tools | Commercial |
| AZT-01 (Therapeutic Nucleases) | Inflammatory & Fibrotic Diseases (e.g., Lupus, RA) | Pre-clinical |
| AZT-02 (Cold-adapted Polymerases) | Enhanced NGS & Diagnostics | Platform Development |
Leadership Team at ArcticZymes Technologies ASA
KE
Knut E. Helland
Chief Executive Officer (CEO)
JK
Jens K. Lassen
Chief Financial Officer (CFO)
TL
Torill L. Pettersen
Chief Commercial Officer (CCO)
BD
Bjørn Dalhus
Chief Scientific Officer (CSO)
MM
Mona M. Johnssen
VP of Research & Development
GM
Gunnar Manum
Chair of the Board
KL
Kari L. H. Otterlei
Board Member
EW
Erik W. L. Røhne
Board Member (Employee Representative)